SFA Therapeutics announces FDA clearance of Investigational New Drug Application to treat NASH and fibrosis

SFA Therapeutics (EFL Life Sciences, ’20) receives FDA clearance for its Investigational New Drug (IND) application. SFA-001N has the potential to address the inflammatory and fibrotic responses associated with NASH.
“This IND clearance represents a significant milestone for SFA Therapeutics. By expanding our pipeline to a new therapeutic area, we have the opportunity to demonstrate that our novel microbiome-derived drug development platform has the potential to address a wide range of auto-immune and chronic inflammatory conditions in multiple organs,” said Ira Spector, Ph.D., CEO of SFA Therapeutics.